Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Aurora A kinase inhibitor JAB-2485

An orally bioavailable small molecule inhibitor of the serine/threonine protein kinase Aurora A, with potential antimitotic and antineoplastic activities. Upon oral administration, Aurora A kinase inhibitor JAB-2485 binds to and inhibits Aurora A kinase, which may result in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, inhibition of cell division and the induction of apoptosis in cells overexpressing Aurora A kinase. Aurora A kinase localizes to the spindle poles and to spindle microtubules during mitosis; it plays an essential role in the regulation of spindle assembly. Aurora kinase A is overexpressed in a wide variety of cancers.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:Aurora A inhibitor JAB-2485
Code name:JAB 2485
JAB-2485
JAB2485
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search